Inhibrx Biosciences (INBX) Assets (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Assets data on file, last reported at $146.5 million in Q4 2025.

• On a quarterly basis, Assets fell 18.97% year-over-year to $146.5 million in Q4 2025; TTM through Dec 2025 was $146.5 million, a 18.97% decrease from a year earlier, with the FY2025 full-year figure at $146.5 million, down 18.97% from the prior year.
• Assets for Q4 2025 stood at $146.5 million, down from $177.5 million in the prior quarter.
• Over the last five years, Assets for INBX reached as high as $307.9 million in Q4 2023 and fell as low as $146.5 million in Q4 2025.
• Historically, Assets has averaged $218.5 million across 3 years, with a median of $217.3 million in 2024.
• Across the five-year window, Assets slumped 41.29% in 2024 and declined 17.92% in 2025, its largest moves.
• Year by year, Assets stood at $307.9 million in 2023, then tumbled by 41.29% to $180.8 million in 2024, then slipped by 18.97% to $146.5 million in 2025.
• Per Business Quant data, the three most recent Assets figures were $146.5 million in Q4 2025, $177.5 million in Q3 2025, and $212.1 million in Q2 2025.